41 results about "Disulfide Linkage" patented technology

The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

The invention discloses a nanometer micelle capable of intelligently releasing medicine as well as a preparation method and an application thereof. The nanometer micelle provided by the invention comprises the components of polyethylene glycol-poly (aspartate-cysteine)-poly (aspartate-diisopropyl ethanediamine). The preparation method comprises the following steps of: firstly, synthesizing PEG-PBLA-N3 and PA-PAsp (DIP); then, taking cuprous bromide / pentamethyldiethylenetriamine as a catalyst system, and synthesizing PEG-PBLA-PAsp (DIP) through a click reaction of PEG-PBLA-N3 and PA-PAsp (DIP); and finally, carrying out an aminolysis reaction on 2-aminoethyl mercaptan to obtain the final polymer PEG-PAsp (MEA)-PAsp (DIP). The nanometer micelle provided by the invention can be used as a hydrophobic medicine carrier. The nanometer micelle is sensitive to pH value, the disulfide bond in the intermediate cross-linking layer is sensitive to a reducing agent, and the nanometer micelle has the characteristic of intelligently releasing medicine.

The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of the multispecific binding molecules comprising polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.

The present invention relates to a curable composition which comprises 1 to 50 parts by weight of an inorganic compound (A) having a sulfur or selenium atom and 50 to 99 parts by weight of a compound (B) represented by the general formula (1): [wherein m is an integer of 0 to 4; and n is an integer of 0 to 2] (with the proviso that the total amount of the compounds (A) and (B) is 100 parts by weight) and which further contains at least one compound (C) selected from the group consisting of thiol compounds each having one SH group and disulfide compounds (except the compound (B)) each having one or more disulfide linkages in an amount of 1 to 20 parts by weight per 100 parts by weight of the total amount of the compounds (A) and (B). The curable composition little causes viscosity increase in prepolymerization or deaeration, and can be therefore cast-polymerized by easy operation into optical elements and so on.

Polymer / copper combination that can selectively target and kill cancer cells are described. Materials can include the reaction product of a biocompatible hydrophilic polymer and pyridine-2-thiol containing monomer. The copolymer reaction product can include pyridine-2-thiol side groups pendant to the backbone via a disulfide linkage. The hydrophilic component can form the polymer backbone and / or can form hydrophilic pendant groups off of the backbone. Copper ions can be associated with the copolymer.

The invention provides methods to prepare protein conjugates from proteins having at least two cysteines. In one embodiment, a protein with a disulfide linkage is reduced to provide two free cysteines for reaction with a 1,3-dihaloacetone or similar reactant, linking the sulfur atoms of the two cysteines together. The ketone inserted between the sulfur atoms is then used to form a Schiff base to an aminated payload molecule, thus conjugating the protein to a payload. In another embodiment, two cysteine residues are tied together by reaction with a 1,3-dihaloacetone or similar reactant. The linkage between the sulfur atoms in each case holds the protein or peptide in a constrained conformation, while also providing a convenient place for attaching a payload with good specificity and efficiency.

The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

The present invention relates to non-aggregating VH domains or libraries thereof. The VH domains comprise at least one disulfide linkage-forming cysteine in at least one complementarity-determining region (CDR) and an acidic isoelectric point (pI). A method of increasing the power or efficiency of selection of non-aggregating VH domains comprises panning a phagemid-based VH domain phage-display library in combination with a step of selecting non-aggregating phage-VH domains. Compositions of matter comprising the non-aggregating VH domains, as well as methods of use are also provided.

Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments covalently linked to a peptide compound through a disulfide linkage. The disulfide linkage is between a cysteine in the Fab region of the antibody or fragment thereof and a thiol moiety of a side chain amino acid of the peptide compound. The covalently formed complexes including provided herein form highly stable and versatile drug delivery and diagnostic compositions.

The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

The invention discloses bovine respiratory syncytial virus antigen protein. Compared with SEQ AAB28458.1, an amino acid sequence of the bovine respiratory syncytial virus antigen protein is characterized in that at least two sites are replaced by cysteines, the replaced cysteines are in disulfide linkage, and improvements such as disulfide linkage, hole filling and single-strand ligation on this basis. The invention further provides a method for preparing the bovine respiratory syncytial virus antigen protein. The bovine respiratory syncytial virus antigen protein and the method for preparing the same have the advantages that technologies and theories of protein crystallography are applied, structural changes of protein in a virus infection and pathopoiesis process are determined, and the key viral protein is subjected to genetic engineering modifications according to structural change results so as to become the antigen protein which is infectious but not pathogenic and capable of causing high-efficiency reaction of animal antigens; the bovine respiratory syncytial virus antigen protein is capable of effectively preventing and treating bovine respiratory syncytial virus infection and is developed into satisfactory viral vaccines on the basis to control and prevent loss brought by virus infection, thereby being of great economic and social significance.

The invention discloses an E.tenella protein disulfide linkage isomerase gene EtPDI (Clone ID is BW1-E06,and the Genbank accession number of is EF552214). The gene is connected with a procaryon expression vector pGEX-4T-2; a procaryon expression recombination plasmid pGEX-4T-EtPDI is constructed and is expressed in a colibacillus system; and most of the expressed recombining protein exists in a soluble form. The recombining protein 4T-EtPDI is purified to carry out SPS-PAGE and is transferred to a PVDF film; and antiserum of E.tenella oocyst oral immunized chicken is used as first resistance and goat anti-chicken IgG is used as second resistance to carry out Western-blot analysis, thereby indicating that the gene has certain antigen. The gene is used for preparing an anti-chicken coccidiosis drug and an anti-chicken coccidiosis vaccine.

The invention discloses a thermostable amylase mutant and a preparation method thereof, which belongs to the field of genetic engineering. According to invention, bacillus alcalophilus JN21 (CCTCC NO:M2011231) amylase is used as female parent; molecular biological technique is adopted to conduct site-directed mutagenesis for bacillus alcalophilus amylase sequence; a pair or multiple pairs of disulfide linkages are introduced in amylase catalytic structural domain to obtain amylase mutant with higher thermal stability; under the modification condition, the half-life period of bacillus alcalophilus amylase at 60 DEG C is improved to 22.3 min from 3.2 min of a comparison example (before mutation); by utilizing the strategy, the thermostability of amylase can be obviously improved to provide basis for industrialized production, and the strategy has significant guiding significance for the modification of properties of other enzymes.

Catalysts of protein-disulfide isomerization of formula:where R1 is hydrogen or —COR4, where R4 is an optionally substituted aliphatic group or an optionally substituted aryl group; R2 is hydrogen or —CO—R5, where R5 is alkyl having 1-8 carbon atoms, an alkenyl having 3-8 carbon atoms or a phenyl, benzyl, phenethyl or naphthyl group; and R3 is hydrogen or alkyl group having 1-3 carbon atoms. Protein folding buffers comprising one or more of the above compounds. Method of catalyzing, in vivo or in vitro, the isomerization of disulfide linkages in a protein or peptide employing above catalysts. Method of forming, in vivo or in vitro, disulfide linkages in a protein or peptide employing above catalysts.

The present invention provides a cell penetrating peptide dimer by oxidative modification, in which each monomer is connected with each other by the disulfide linkage. The drugability of the peptide dimer has been improved through enhancing stability, reducing proteolysis, retaining permeability and increasing heparan sulfate binding specificity. The modified peptide products can be used to deliver drug molecules as a suitable drug carrier for targeted therapy.

The invention discloses a nanometer micelle capable of intelligently releasing medicine as well as a preparation method and an application thereof. The nanometer micelle provided by the invention comprises the components of polyethylene glycol-poly (aspartate-cysteine)-poly (aspartate-diisopropyl ethanediamine). The preparation method comprises the following steps of: firstly, synthesizing PEG-PBLA-N3 and PA-PAsp (DIP); then, taking cuprous bromide / pentamethyldiethylenetriamine as a catalyst system, and synthesizing PEG-PBLA-PAsp (DIP) through a click reaction of PEG-PBLA-N3 and PA-PAsp (DIP); and finally, carrying out an aminolysis reaction on 2-aminoethyl mercaptan to obtain the final polymer PEG-PAsp (MEA)-PAsp (DIP). The nanometer micelle provided by the invention can be used as a hydrophobic medicine carrier. The nanometer micelle is sensitive to pH value, the disulfide bond in the intermediate cross-linking layer is sensitive to a reducing agent, and the nanometer micelle has the characteristic of intelligently releasing medicine.